Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT

Kanthan, Gowri L.; Coyle, Luke; Kneebone, Andrew; Schembri, Geoffrey; Hsiao, Edward

doi:10.1097/rlu.0000000000001169

Cited by 58 publications

(29 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, there is increasing evidence that PSMA ligand uptake is not exclusively specific for PC. A large number of case series and reports describe increased PET signal in benign lesions (e.g., neurogenic tissue, Paget disease, thyroid adenoma, granulomatous disease, and adrenal adenoma) as well as in malignant diseases (e.g., renal cell carcinoma, lung cancer, glioblastoma, hepatocellular carcinoma, and thyroid cancer) (87)(88)(89)(90)(91)(92)(93)(94)(95). Supplemental Table 1 (supplemental materials are available at http://jnm.snmjournals.org) summarizes the current evidence in the literature.…”

Section: Limitations and Pitfalls In Clinical Interpretationmentioning

confidence: 99%

PSMA Ligands for PET Imaging of Prostate Cancer

et al. 2017

View full text Add to dashboard Cite

Section: Limitations and Pitfalls In Clinical Interpretationmentioning

confidence: 99%

PSMA Ligands for PET Imaging of Prostate Cancer

et al. 2017

View full text Add to dashboard Cite

“…68Ga-PSMA is a valuable tool in the assessment and management of advanced prostate cancer patients. However, a wide range of malignancies other than prostate cancer have also been reported to express PSMA as part of tumor neovasculature [ 7 – 9 ] with 68Ga-PSMA avidity described in cases of breast cancer [ 10 ], renal cell carcinoma [ 11 ], glioblastoma multiforme [ 12 ], hepatocellular carcinoma [ 13 ], differentiated thyroid cancer [ 14 ], colorectal carcinoma [ 15 ], non-small cell lung cancer [ 16 ] and follicular lymphoma [ 17 ]. PSMA uptake has been also reported in a large variety of benign lesions such as retroperitoneal schwannoma [ 18 ], desmoid tumor [ 19 ], Paget’s disease of bone [ 20 ], sarcoidosis [ 21 ], sub-acute stroke [ 22 ] and bone fractures [ 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

68Ga-PSMA PET/CT in prostate cancer patients – patterns of disease, benign findings and pitfalls

et al. 2018

View full text Add to dashboard Cite

Background68Ga-PSMA PET/CT has an important role in assessment of prostate cancer patients with biochemical recurrence and is evolving in staging high- and intermediate risk disease. The aim of present study was to describe the metastatic patterns and frequency of involved sites of prostate cancer and to assess the incidence of benign Ga68-PSMA avid PET/CT findings in a large patient population.Methods68Ga-PSMA PET/CT studies performed in two tertiary medical centers over a period of 24 months were retrospectively reviewed. The incidence and location of pathological 68Ga-PSMA avid foci, suspicious to represent malignancy, as well as those of unexpected benign foci of increased 68Ga-PSMA activity were documented and analyzed.ResultsThere were 445 68Ga-PSMA studies in 438 men (mean age 72.4, range 51–92 years) with prostate cancer referred for biochemical failure (n = 270, 61%), staging high-risk disease (n = 112, 25%), response assessment (n = 30, 7%), follow-up (n = 22, 5%) and suspected bone metastases (n = 11, 2%). 68Ga-PSMA avid disease sites were observed in 319 studies (72%), in 181 studies (67%) for biochemical recurrence, 94 studies for staging (84%) (p < 0.05), in 22 studies for response assessment (73%), 10 follow up studies (45%) and in five patients with suspected bone metastases (45%). 68Ga-PSMA avid lesions were most commonly detected in the prostate (n = 193, 43%), loco-regional spread (n = 51, 11%), abdomino-pelvic nodes (n = 129, 29%) and distant metastases (n = 158, 36%), including bone metastases (n = 11, 25%), distant lymphadenopathy (n = 29, 7%) and other organs (n = 18, 4%). Distant 68Ga-PSMA-avid metastases were commonly seen in patients with biochemical recurrence (14/21 lesions), but were not seen in patient referred for staging (p < 0.013). There were 96 non-malignant 68Ga-PSMA avid foci in 81 studies, most common in reactive lymph nodes (n = 36, 38%), nonmalignant bone lesions (n = 21, 22%), thyroid nodules (n = 9, 9%), ganglions (n = 9, 9%) and lung findings (n = 8, 8%).ConclusionThe distribution of 68Ga-PSMA avid metastatic lesions is similar to data previously reported mainly from autopsy with comparable detection rates, indicating 68Ga-PSMA PET/CT is an accurate detection tool in patients with metastatic prostate cancer. If confirmed by further prospective studies 68Ga-PSMA PET/CT should be included in the guidelines to evaluate disease extent in these patients.

show abstract

“…Nevertheless, PSMA expression is not specific to prostate tissue. Benign neoplasms such as schwannoma and thyroid follicular adenoma and several malignant neoplasms such as renal cell carcinoma, colon carcinoma, neuroendocrine tumours, melanoma, breast cancer, desmoid tumour, lymphoma and differentiated thyroid carcinoma may also express PSMA. In addition, various normal organs such as salivary glands, lacrimal glands, kidneys and liver demonstrate physiological expression of PSMA.…”

Section: Introductionmentioning

confidence: 99%